New combo aims to tame GVHD after stem cell transplants

NCT ID NCT07576010

Ongoing Disease control Sponsor: Daihong Liu Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether combining a low-dose steroid with the drug ruxolitinib can better control grade II acute graft-versus-host disease (GVHD) after a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body. The trial includes 30 people with certain blood cancers who have received a transplant. Researchers will track how long patients stay free of severe GVHD, relapse, or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-dose methylprednisolone (steroid) plus ruxolitinib
What this could lead to: If successful, this could offer a more effective first-line treatment for grade II acute GVHD, reducing the need for stronger immunosuppression and improving outcomes after stem cell transplant.
What could go wrong: This is a very early Phase 1 study with only 30 participants, so results may not apply broadly. The combination may cause side effects or fail to improve survival compared to standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.